ORIENTBIO Inc. (KO:002630) — Market Cap & Net Worth
Market Cap & Net Worth: ORIENTBIO Inc. (002630)
ORIENTBIO Inc. (KO:002630) has a market capitalization of $69.59 Million (₩102.69 Billion) as of August 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #20559 globally and #1100 in its home market, demonstrating a -11.63% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying ORIENTBIO Inc.'s stock price ₩866.00 by its total outstanding shares 118583005 (118.58 Million). See 002630 capex reinvestment rate to understand how much of operating cash flow is reinvested back into capital assets.
ORIENTBIO Inc. Market Cap History: 2015 to 2026
ORIENTBIO Inc.'s market capitalization history from 2015 to 2026. Data shows change from $225.99 Million to $69.59 Million (-9.91% CAGR).
ORIENTBIO Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how ORIENTBIO Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
ORIENTBIO Inc.'s market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $291.18 Million | $105.05 Billion | -$3.01 Billion | 0.00x | N/A |
| 2017 | $187.75 Million | $109.02 Billion | -$19.13 Billion | 0.00x | N/A |
| 2018 | $102.29 Million | $121.21 Billion | -$13.87 Billion | 0.00x | N/A |
| 2019 | $54.66 Million | $30.37 Billion | -$19.51 Billion | 0.00x | N/A |
| 2020 | $101.66 Million | $37.70 Billion | -$10.88 Billion | 0.00x | N/A |
| 2021 | $98.04 Million | $52.02 Billion | -$15.27 Billion | 0.00x | N/A |
| 2022 | $49.26 Million | $26.28 Billion | $34.20 Billion | 0.00x | 0.00x |
| 2023 | $48.78 Million | $28.82 Billion | -$12.42 Billion | 0.00x | N/A |
| 2024 | $124.32 Million | $28.01 Billion | $12.87 Billion | 0.00x | 0.01x |
| 2025 | $48.30 Million | $29.40 Billion | -$13.19 Billion | 0.00x | N/A |
Competitor Companies of 002630 by Market Capitalization
Companies near ORIENTBIO Inc. in the global market cap rankings as of August 4, 2026.
Key companies related to ORIENTBIO Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #423 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #541 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #564 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $470.72 |
| #423 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $759.24 |
| #541 | Argen-X | BR:ARGX | $49.55 Billion | €722.20 |
| #564 | UCB SA | BR:UCB | $47.34 Billion | €221.40 |
ORIENTBIO Inc. Historical Marketcap From 2015 to 2026
Between 2015 and today, ORIENTBIO Inc.'s market cap moved from $225.99 Million to $ 69.59 Million, with a yearly change of -9.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩69.59 Million | +44.09% |
| 2025 | ₩48.30 Million | -61.15% |
| 2024 | ₩124.32 Million | +154.86% |
| 2023 | ₩48.78 Million | -0.98% |
| 2022 | ₩49.26 Million | -49.75% |
| 2021 | ₩98.04 Million | -3.56% |
| 2020 | ₩101.66 Million | +85.97% |
| 2019 | ₩54.66 Million | -46.56% |
| 2018 | ₩102.29 Million | -45.52% |
| 2017 | ₩187.75 Million | -35.52% |
| 2016 | ₩291.18 Million | +28.85% |
| 2015 | ₩225.99 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of ORIENTBIO Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $69.59 Million USD |
| MoneyControl | $69.59 Million USD |
| MarketWatch | $69.59 Million USD |
| marketcap.company | $69.59 Million USD |
| Reuters | $69.59 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About ORIENTBIO Inc.
ORIENT BIO Inc. operates in the bio-industry in South Korea and internationally. It engages in the production, export, import, and life science-related research and development of laboratory animals; and offers various equipment for research environment. The company also provides infrastructural solution; health checking; generic testing; molecular biological generic testing; generic transformati… Read more